10 'Minor' Cannabinoids Tested for Pain Relief: THCP and CBC Were the Most Potent

In vitro study using adult rat DRG neurons cultured with nerve growth factor (100 ng/mL) and GDNF (50 ng/mL) for 48 hours to sensitize nociceptors. Calcium imaging measured neuronal responses to capsaicin stimulation, and the modulatory effects of 10 minor cannabinoids at concentrations of 0.001-100 μM were assessed in individual neurons.

Neuropathic pain is one of the greatest unmet clinical needs in medicine. Current treatments fail about 50% of patients. Minor cannabinoids represent a largely unexplored pharmacological frontier. This systematic comparison of 10 cannabinoids on pain-sensing neurons provides the foundational data needed to identify which minor cannabinoids are most worth pursuing in animal models and eventually human trials.

This study expands the cannabinoid toolkit beyond the two compounds (THC and CBD) that dominate research and commerce. The CBG research in RTHC-00097 (rheumatoid arthritis) and the CBD immune work in RTHC-00098 have already shown that non-THC cannabinoids have biological activity. This study goes further by systematically comparing 10 minor cannabinoids head-to-head for pain-relevant activity. THCP's potency at low concentrations is particularly interesting because it could potentially provide pain relief at doses below the threshold for psychoactive effects.

In vitro study using rat neurons — several steps removed from human clinical relevance. The capsaicin challenge model assesses one type of pain signaling (TRPV1-mediated) and may not represent all neuropathic pain mechanisms. Dose-response relationships in isolated neurons don't predict effective doses in living animals or humans. No comparison to THC or CBD in the same assay, making it hard to benchmark the minor cannabinoids. Cannabinoid metabolism, distribution, and brain penetration — critical for clinical efficacy — aren't addressed.